Adma Biologics (ADMA) Payables (2011 - 2025)

Adma Biologics has reported Payables for 15 years, with the latest figure at $22.5 million in Q4 2025.

• For the quarter ending Q4 2025, Payables rose 11.38% year-over-year to $22.5 million; the trailing twelve-month figure through Dec 2025 stood at $22.5 million (up 11.38% YoY), and the FY2025 full-year result was $22.5 million, up 11.38% from the prior year.
• Payables for Q4 2025 stood at $22.5 million, down from $24.0 million in the prior quarter.
• The five-year high for Payables was $112.2 million in Q1 2021, with the low at $6.2 million in Q2 2021.
• Historically, Payables has averaged $21.4 million across 5 years, with a median of $15.8 million in 2023.
• The largest YoY upside for Payables was 1125.41% in 2021 against a maximum downside of 92.74% in 2021.
• Adma Biologics' Payables stood at $12.4 million in 2021, then increased by 6.43% to $13.2 million in 2022, then increased by 18.38% to $15.7 million in 2023, then gained by 29.11% to $20.2 million in 2024, then increased by 11.38% to $22.5 million in 2025.
• The last three Payables figures came in at $22.5 million (Q4 2025), $24.0 million (Q3 2025), and $29.8 million (Q2 2025), per Business Quant data.